Sensitizing EGFR mutations (EGFR L858R, exon 19 deletion, or L861Q/G719X/S786I) were by far the most prevalent druggable target, being observed in 78.5% of lung cancer samples with guideline-approved biomarkers, while EGFR T790M, exon 20 insertions, and amplifications, were also observed at significant frequencies (Fig 5E bottom). The gene discussed is EGFR; the disease is lung carcinoma.